UroGen Is A Compelling Value With Recent FDA Approval [Seeking Alpha]
Alphabet Inc. - Class C Capital Stock (GOOG)
Last alphabet inc. - class c capital stock earnings: 4/28 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
abc.xyz/investor
Company Research
Source: Seeking Alpha
SummaryUGN-101/Jelmyto was recently "fast-tracked" FDA approved as a "breakthrough" orphan therapy for ~7,000 patients/year (6 doses at $21,376/dose) for a ~$900 million (gross/pre-discount) annual revenue opportunity.UGN-102 Phase IIb data just released demonstrated 65% CR (complete responses) with 85% 9-month durability. Phase III trial to start 2H2020. UGN-102 patient population ~80,000/year.Urogen Pharma had $196 million cash at 12/31/2019, no debt and forecasts $110-116 million in FY2020 cash operating expenses. Material dilution risk until the company breaks even appears minimal.At $24/share, the company's enterprise valuation is only ~$310 million. It forecasts UGN-101 and UGN-102 potential peak revenues (excluding an impressive pipeline) in excess of $1 billion.Because UGN-101 reimbursement is expected in Q42020 and UGN-102's Phase II trial just completed, it's ideal timing for a buyout so a buyer controls the commercial launch and Phase III design.Urogen Pharma Ltd. (URGNURGN
Show less
Read more
Impact Snapshot
Event Time:
GOOG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOOG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOOG alerts
High impacting Alphabet Inc. - Class C Capital Stock news events
Weekly update
A roundup of the hottest topics
GOOG
News
- Alphabet (NASDAQ:GOOG) had its "buy" rating reaffirmed by analysts at Pivotal Research.MarketBeat
- Walmart-backed PhonePe winds down its Pincode app in yet another e-commerce step back [TechCrunch]TechCrunch
- How Kit Kat Was Killed: Video Shows What a Waymo Couldn’t See [The New York Times]The New York Times
- A safety report card ranks AI company efforts to protect humanity [Los Angeles Times (CA)]Los Angeles Times
- 'Godfather of AI' Geoffrey Hinton says Google is 'beginning to overtake' OpenAI: 'My guess is Google will win' [Business Insider]Business Insider
GOOG
Earnings
- 10/29/25 - Beat
GOOG
Sec Filings
- 12/3/25 - Form 144
- 12/3/25 - Form 144
- 12/2/25 - Form 4
- GOOG's page on the SEC website